Filter by
 

Origin

Publication date

Category

Main subject

Main subject

Keywords

Keywords

Geographical scope

Document language

EMCDDA Document Library

Displaying 41 - 50 of 85

Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization’s global health sector strategy core indicators and scaling up key interventions

March 2017

It is estimated that ca 4.7 million people living in European Union (EU) and European Economic Area (EEA) countries are chronically infected with the hepatitis B virus (HBV) and 5.6 million have been infected with the hepatitis C virus (HCV). Both are major causes of chronic liver disease, liver...

Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England

February 2017

This scientific article was one of the 2018 EMCDDA scientific award winners, which celebrates scientific writing and distinguishes high-quality research in the field of illicit drugs. This article won the award in the category ' Demand reduction interventions' and the award was granted to first...

HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden

December 2016

In Hungary a large increase in injecting new psychoactive substances (NPS) coincided with decreasing harm reduction efforts and rising HCV infection. NPS injectors in Hungary are at severe risk of blood-borne infections due to high levels of injecting and sexual risk behaviours within a high-risk...

New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe

December 2016

This scoping study was based on a targeted multi-source data collection exercise focusing on the provision of health and drug interventions associated with NPS use and harms, in selected intervention settings across Europe.

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference

January 2016

In June 2014 the Athens High Level Meeting discussed recent policy developments, persisting and emerging challenges related to the prevention and management of viral hepatitis and the need for a de minimis framework of urgent priorities for action.

HCV promotional material example: Löffel, Filter, Wasser: Konsumutensilien und Hepatitis B/C - Kurzinfos für Drogengebraucher

January 2016

The leaflet covers information about hepatitis C, B and HIV, and related infection risks. It is a brief information for drug users. It was produced based on the outcomes from the DRUCK Studie.

HCV promotional material example: Hepatitis B and C testing: Why? Who? How?

January 2016

A guidance paper on testing in community and harm reduction settings. The paper includes the key facts about hepatitis B and C; Harm reduction as prevention; key recommendations about awareness raising and testing and diagnosis. The main topic covered in the paper is about different screening...

HCV promotional material example: Hepatitis. Das Wichtigste in Kürze

January 2016

The leaflet contains information about the key facts about hepatitis; the screening technologies and target group; the prevention of hepatitis, and the treatment.

Review of European-Drug Emergencies Network (Euro-DEN) training package for non-specialist workers to assess acute recreational drug and new psychoactive substance toxicity in night-time economy environments

September 2015

The initial management of acute recreational drug and new psychoactive substance (NPS) toxicity is often by non-specialists working in the night-time economy. The aim was as part of the European Drug Emergencies Network (Euro-DEN) project to pilot training of these workers in multiple European...

Council conclusions on the implementation of the EU Action Plan on Drugs 2013-2016 regarding minimum quality standards in drug demand reduction in the European Union

September 2015

In September 2015, the Council of the European Union adopted Council conclusions on the implementation of minimum quality standards in drug demand reduction in the EU. This innovative initiative lists 16 standards that represent a minimum benchmark of quality for interventions in: drug use...

Loading